STOCK TITAN

Director at MAIA Biotechnology (MAIA) receives 32,003 stock options grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

MAIA Biotechnology director Stan Smith reported a grant of stock options. On June 30, 2026, he was awarded 32,003 stock options under the company’s 2021 Equity Incentive Plan, each with an exercise price of $1.44 per share. The options vest 100% on the grant date and are immediately exercisable for up to 32,003 shares of common stock. Following this compensation-related award, he holds 32,003 options indirectly through The Stan V. Smith Trust Dated 1993.

Positive

  • None.

Negative

  • None.
Insider Smith Stan
Role null
Type Security Shares Price Value
Grant/Award Stock Options 32,003 $0.00 --
Holdings After Transaction: Stock Options — 32,003 shares (Indirect, See footnote)
Footnotes (1)
  1. The stock options, granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.
Options granted 32,003 stock options Grant to Stan Smith on June 30, 2026
Exercise price $1.44 per share Exercise price for granted stock options
Underlying shares 32,003 shares Common stock underlying the stock options
Expiration date June 30, 2036 Option expiration for Stan Smith’s grant
2021 Equity Incentive Plan financial
"granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan"
Stock Options financial
"The stock options, granted on June 30, 2026 pursuant to the MAIA Biotechnology"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
Common Stock financial
"representing the right to buy shares of common stock, vest 100% on the date"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
beneficially owned financial
"These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Trust financial
"beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993"
A trust is a legal setup in which one party (the trustee) holds and manages assets—like cash, stocks or property—on behalf of other people (beneficiaries) according to instructions from the person who created it (the grantor). Think of it as a locked box with a keyholder who must follow written rules; for investors it matters because trusts influence who controls and benefits from assets, affect taxes and succession, and can change how quickly or transparently shares are bought, sold or voted.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Smith Stan

(Last)(First)(Middle)
444 WEST LAKE STREET, SUITE 1700

(Street)
CHICAGO ILLINOIS 60606

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
MAIA Biotechnology, Inc. [ MAIA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Options$1.4406/30/2026A32,00306/30/2026(1)06/30/2036Common Stock32,003$032,003ISee footnote(2)
Explanation of Responses:
1. The stock options, granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
2. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.
/s/ Stan V. Smith07/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did MAIA director Stan Smith report on this Form 4?

Director Stan Smith reported receiving a grant of 32,003 stock options in MAIA Biotechnology. These options were awarded as compensation, not bought on the open market, and give him the right to acquire an equal number of common shares at a fixed exercise price.

What are the key terms of Stan Smith’s MAIA stock option grant?

Stan Smith’s grant covers 32,003 stock options with an exercise price of $1.44 per share. The options were granted under MAIA Biotechnology’s 2021 Equity Incentive Plan and vest 100% on the grant date, making them immediately exercisable for common stock.

When do Stan Smith’s MAIA stock options vest and expire?

The stock options granted to Stan Smith vest 100% on June 30, 2026, the grant date. They are exercisable beginning that same date and remain outstanding until their expiration on June 30, 2036, giving a long window in which they may be exercised.

How are Stan Smith’s MAIA stock options held according to the Form 4?

The Form 4 states these securities are beneficially owned through The Stan V. Smith Trust Dated 1993. This means the options are reported as indirectly owned, with the trust holding the position while still being attributed to Stan Smith for reporting purposes.

How many MAIA stock options does Stan Smith hold after this transaction?

After the reported grant, Stan Smith holds 32,003 stock options related to MAIA Biotechnology. The filing lists 32,003 derivative securities following the transaction, each representing the right to buy one share of MAIA common stock at the stated exercise price.

Is Stan Smith’s MAIA transaction a market purchase or a compensation award?

The transaction is a compensation-related award, not a market purchase. The Form 4 uses transaction code A, described as a grant, award, or other acquisition, with a transaction price per share of $0.00 and a separate exercise price set at $1.44 per share.